LNA-Modified Antisense Oligonucleotides for TGF-beta2 Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapeutic agents fail to effectively reduce or inhibit TGF-beta expression and activity without causing severe side effects, particularly in the treatment of TGF-beta linked diseases such as cancer and fibrosis, due to lack of specificity and high potential for off-target effects.
Innovation Solution
Development of antisense oligonucleotides comprising 10 to 18 nucleotides complementary to the TGF-beta2 nucleic acid sequence with LNA modifications, specifically designed to interact with TGF-beta mRNA, reducing or inhibiting TGF-beta expression and activity while minimizing off-target effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional therapeutic agents are used to inhibit TGF-beta expression, then TGF-beta activity is reduced, but off-target effects and severe side effects occur due to lack of specificity
Solution Approach 1:
The patent segments the therapeutic approach by using short oligonucleotide sequences (10-18 nucleotides) that specifically target only the TGF-beta2 mRNA sequence, rather than using broad-spectrum conventional agents. This segmentation allows precise inhibition of TGF-beta2 without affecting other proteins or pathways, thereby eliminating off-target effects while maintaining therapeutic efficacy
Solution Approach 2:
The patent applies local quality by introducing LNA modifications at specific positions within the oligonucleotide sequence (particularly at the 5' and 3' ends and at positions corresponding to GC-rich regions). These localized modifications enhance binding affinity and specificity to the TGF-beta2 mRNA target sequence, improving reliability of inhibition while minimizing non-specific interactions that cause side effects
2Reliability
If oligonucleotides are designed to be short (10-18 nucleotides) for high specificity, then off-target effects are minimized, but binding affinity and stability may be reduced
Solution Approach 1:
The patent changes the chemical parameters of the oligonucleotide by incorporating LNA (locked nucleic acid) modifications. This parameter change fundamentally alters the binding properties - LNA modifications increase the melting temperature (Tm) by 2-8°C per modification, dramatically enhancing binding affinity and stability. This allows the use of short sequences (10-18 nucleotides) for high specificity while the LNA modifications compensate for the reduced length by providing superior binding strength and nuclease resistance
Solution Approach 2:
The patent creates a composite oligonucleotide structure combining natural nucleotides with LNA-modified nucleotides in specific patterns. This composite approach allows the molecule to maintain the sequence specificity of natural nucleotides while gaining the enhanced stability and affinity of LNA modifications, achieving both high specificity and strong binding in a single therapeutic agent
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The LNA-modified oligonucleotides demonstrate significant inhibition of TGF-beta expression and activity, effectively preventing and treating malignant and benign tumors, immunologic diseases, and fibrosis with low toxicity and minimal side effects, as shown by their ability to reduce TGF-beta mRNA and protein levels in cancer cells.
Implementation Method 1
oligonucleotides consisting of 10 to 18 nucleotides hybridizing with the TGF-beta2 nucleic acid sequence
Data Source
Figure 1
Figure 2
Figure 3a
AI summary
The invention refers to an oligonucleotide consisting of 10 to 18 nucleotides of selected regions of the TGF-beta2 nucleic acid sequence, which comprises modified nucleotides such as LNA, ENA, polyalkylene oxide-, 2'-fluoro, 2'-O-methoxy and/or 2'-O-methyl modified nucleotides. The invention further relates to pharmaceutical compositions comprising such oligonucleotide, wherein the composition or the oligonucleotide is used in the prevention and/or treatment of a malignant and/or benign tumor, an immunologic disease, fibrosis, or an ophthalmic disease such as dry eye, glaucoma or posterior capsular opacification (PCO).